explore -WSS

explore

author：fashion 2025-10-01 02:14:21 - browse：14

An illustrated portrait of Eli Lilly's David Ricks and Skovronsky – biotech and pharma coverage from STAT — Eli Lilly CEO David Ricks (left) and Chief Scientific Officer Daniel S. Skovronsky Molly Ferguson for STAT

The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition.

At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm. But what struck Ricks was not the company’s technology, for imaging Alzheimer’s plaques, but Avid’s CEO, Daniel S. Skovronsky.

“Dan’s different,” Ricks told STAT. “I had this sense immediately. Some people get in biotech for the cha-ching.” Skovronsky turned out to be a secret weapon. Within six months, Ricks had been promoted to run Lilly’s biomedicine unit and Skovronsky was working for him.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： AstraZeneca stays mum on Medicare drug pricing negotiations

WSS

Updated Covid vaccine has 54% effectiveness, new study suggests

Bernie brings in new pharma CEOs to talk drug prices

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Popular nasal decongestant doesn't actually relieve congestion

A single Democrat is willing to weaken Medicare negotiation power

Long Covid needs a new name — and a new frame

leisure time

explore

Wikipedia

Supreme Court strikes down use of affirmative action

A single Democrat is willing to weaken Medicare negotiation power

Jerome Adams on the need for new antivirals for Covid

The Biogen Aduhelm mess could happen again

In Memoriam: Notable people who died in 2023

Will the IRA bring competition to the biologics market?

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Top private equity targets in 2023: cardiology, clinical trials, lasers

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Problems with a popular proposal to regulate AI in health care

hotspot

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

Walmart eyes Medicare Advantage provider ChenMed

340B reform proposal comes out of Senate working group

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Food makers to regulators: Ultra

Private equity could exacerbate cardiology's overuse problem, experts fear

focus

explore

hotspot

hotspot